Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 22 April 2015 | By Michael Mezher
The European Court of Justice (ECJ) has issued a judgment clarifying EU transparency rules for products covered by national health insurance as they apply to ongoing legal battles in France.
The judgement pertains to two complaints filed against France's Minister for Finance and Public Accounts and the Minister for Social Affairs and Health over the removal of two medicines from the list of products covered by the country's health insurance scheme.
The medicines in question are Alfalastin and Javlor, made by LFB Biomédicaments (LFB) and Pierre Fabre Médicament (PFM), respectively.
On 21 February 2012, a decree by the French government removed the medicines from the list of products covered by the national health insurance scheme. While the decree removed the products from the aforementioned list, they were still paid for by health insurance through fixed payments for the duration of hospitalization.
The plaintiffs in the case argued that the government was required to state its reasons for removing the products from the list, as the decree had the potential to lower the amount of reimbursement for their products. The French government countered by saying the decree did not, in effect, prevent the products from being covered.
The issue at the center of this case is whether the French government is required to give notice and reasoning to a company when a product's coverage is restricted.
The companies in the suits point to requirements found in Article 6(3) and 6(5) of Council Directive 89/105/EEC, which state:
"Article 6 – The following provisions shall apply if a medicinal product is covered by the national health insurance system only after the competent authorities have decided to include the medicinal product concerned in a positive list of medicinal products covered by the national health insurance system:3. Before the date [31 December 1989] referred to in Article 11 (1), Member States shall publish in an appropriate publication and communicate to the Commission the criteria which are to be taken into account by the competent authorities in deciding whether or not to include medicinal products on the lists.5. Any decision to exclude a product from the list of products covered by the health insurance system shall contain a statement of reasons based on objective and verifiable criteria. Such decisions, including, if appropriate, any expert opinions or recommendations on which the decisions are based, shall be communicated to the person responsible, who shall be informed of the remedies available to him under the laws in force and the time limits allowed for applying for such remedies."
"Article 6 – The following provisions shall apply if a medicinal product is covered by the national health insurance system only after the competent authorities have decided to include the medicinal product concerned in a positive list of medicinal products covered by the national health insurance system:
3. Before the date [31 December 1989] referred to in Article 11 (1), Member States shall publish in an appropriate publication and communicate to the Commission the criteria which are to be taken into account by the competent authorities in deciding whether or not to include medicinal products on the lists.5. Any decision to exclude a product from the list of products covered by the health insurance system shall contain a statement of reasons based on objective and verifiable criteria. Such decisions, including, if appropriate, any expert opinions or recommendations on which the decisions are based, shall be communicated to the person responsible, who shall be informed of the remedies available to him under the laws in force and the time limits allowed for applying for such remedies."
3. Before the date [31 December 1989] referred to in Article 11 (1), Member States shall publish in an appropriate publication and communicate to the Commission the criteria which are to be taken into account by the competent authorities in deciding whether or not to include medicinal products on the lists.
5. Any decision to exclude a product from the list of products covered by the health insurance system shall contain a statement of reasons based on objective and verifiable criteria. Such decisions, including, if appropriate, any expert opinions or recommendations on which the decisions are based, shall be communicated to the person responsible, who shall be informed of the remedies available to him under the laws in force and the time limits allowed for applying for such remedies."
France's Conseil d’État (Council of the State), which originally heard the cases last year, found that the decree in question did not have "the effect of excluding the medicinal products … from the list of proprietary products covered by health insurance," as the products are still paid for by fixed payments during hospitalization. However, the companies argued that Articles 6(3) and 6(5) of Council Directive 89/105/EEC still apply, as previous judgments have led to the Article 6 being interpreted broadly by the courts.
To get clarification on the issue, the Conseil d’État forwarded its questions to the ECJ. The ECJ accepted the companies' claim, finding that even though the decree did not exclude the products from coverage, "the decision does change the terms or level of reimbursement for those medicinal products and may thus restrict the conditions of reimbursement or reduce the level of coverage."
The ECJ went on to rule that the intent of Council Directive 89/105/EEC is to "ensure transparency of pricing … and to provide public access to pricing arrangements for all those involved."
In this view, the ECJ ruled that Member States must give reasons per Articles 6(3) and 6(5) for any "decision which restricts the conditions of reimbursement or reduces the level of coverage of a medicinal product by excluding it from the list of proprietary medicinal products covered by compulsory health insurance schemes in addition to services relating to hospital treatment covered by fixed payments in respect of periods of hospitalization and hospital care."
ECJ Ruling
Tags: European Court of Justice, ECJ, Alfalastin, Javlor
Regulatory Focus newsletters
All the biggest regulatory news and happenings.